Should I buy or sell Fulgent Genetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FLGT shares. View FLGT analyst ratings or view top-rated stocks .

What is Fulgent Genetics' stock price target for 2024?

2 equities research analysts have issued 12 month price targets for Fulgent Genetics' stock. Their FLGT share price targets range from $28.00 to $45.00. On average, they predict the company's share price to reach $36.50 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price. View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts .

How have FLGT shares performed in 2023?

Fulgent Genetics' stock was trading at $29.78 on January 1st, 2023. Since then, FLGT shares have decreased by 12.9% and is now trading at $25.95. View the best growth stocks for 2023 here .

When is Fulgent Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our FLGT earnings forecast .

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) released its quarterly earnings data on Friday, November, 3rd. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.07. The firm had revenue of $84.70 million for the quarter, compared to analyst estimates of $64.42 million. Fulgent Genetics had a negative net margin of 22.17% and a negative trailing twelve-month return on equity of 4.59%. The business's revenue for the quarter was down 19.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.11 EPS.

What ETFs hold Fulgent Genetics' stock?

ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) , Global X Genomics & Biotechnology ETF (GNOM) , SPDR S&P Health Care Services ETF (XHS) and Invesco S&P SmallCap Health Care ETF (PSCH) . First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) .

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its FY23 earnings guidance on Friday, November, 3rd. The company provided earnings per share (EPS) guidance of ($0.95) for the period, compared to the consensus EPS estimate of ($0.95).

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA) , CRISPR Therapeutics (CRSP) , Inseego (INSG) , NeoGenomics (NEO) , Invitae (NVTA) , Block (SQ) , JD.com (JD) , Marvell Technology (MRVL) , Teladoc Health (TDOC) and Editas Medicine (EDIT) .

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Invesco Ltd. (1.06%), American Century Companies Inc. (0.86%), Charles Schwab Investment Management Inc. (0.79%), Northern Trust Corp (0.76%), Bank of New York Mellon Corp (0.71%) and Principal Financial Group Inc. (0.39%). Insiders that own company stock include Hanlin Gao , Jian Xie , John C Bolger , Paul Kim and X Cycle LP Tcv. View institutional ownership trends .

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Fulgent Genetics have any subsidiaries?

The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics. Read More

Fulgent Genetics Stock Price, News & Analysis (NASDAQ:FLGT)

$25.95

-1.52 (-5.53%)

(As of 12/5/2023 ET)

Compare

Today's Range: $25.91
▼
$27.28
50-Day Range: $23.64
▼
$27.93
52-Week Range: $23.09
▼
$44.09

Volume: 234,830 shs
Average Volume: 220,270 shs
Market Capitalization: $768.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.50

Fulgent Genetics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 40.7% Upside
$36.50 Price Target
Short Interest: Bearish
4.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.84
Based on 2 Articles This Week
Insider Trading: Selling Shares
$159,241 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.09) to ($1.92) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

213th out of 948 stocks

Diagnostics & Research Industry

4th out of 5 stocks

3.3

Analyst's Opinion

Consensus Rating
Fulgent Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.50, Fulgent Genetics has a forecasted upside of 40.7% from its current price of $25.95.
Amount of Analyst Coverage
Fulgent Genetics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.93% of the float of Fulgent Genetics has been sold short.
Short Interest Ratio / Days to Cover
Fulgent Genetics has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Fulgent Genetics has recently increased by 3.11%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Fulgent Genetics does not currently pay a dividend.
Dividend Growth
Fulgent Genetics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fulgent Genetics is -0.67.

2.1

News and Social Media Coverage

News Sentiment
Fulgent Genetics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $159,241.00 in company stock.
Percentage Held by Insiders
31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
46.09% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Fulgent Genetics are expected to grow in the coming year, from ($2.09) to ($1.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fulgent Genetics is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fulgent Genetics is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fulgent Genetics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fulgent Genetics Stock (NASDAQ:FLGT)

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

FLGT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FLGT Stock News Headlines

December 3, 2023 | finance.yahoo.com

The 3 Best Digital Health Stocks for Personalized Medicine

December 1, 2023 | seekingalpha.com

Following Up On Fulgent Genetics

December 6, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

November 14, 2023 | businesswire.com

Fulgent to Participate in the Piper Sandler 35 th Annual Healthcare Conference

November 14, 2023 | finance.yahoo.com

Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference

November 5, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript